Case Studies

Diana M. Sobieraj, PharmD, and Craig I. Coleman, PharmD
Published Online: Friday, May 17, 2013
Follow Pharmacy_Times:
Case 1
SD is a 59-year-old man with stable coronary artery disease and exertional angina that is being medically managed. He also suffers from chronic obstructive pulmonary disease (COPD), hyperlipidemia, and is a current smoker. SD has received a trial of metoprolol succinate, requiring the maximal dose for angina relief. Unfortunately, SD was unable to tolerate the exacerbation of his COPD symptoms that resulted. SD has also tried nitrates, but had to discontinue therapy because he suffered intolerable headaches.
What other therapies are available for the treatment of SD’s angina?

Case 2
MJ is a 63-year-old woman with type 2 diabetes, hypertension, and mild heart failure. Her glycemic control is consistently suboptimal (A1C = 7.9%) despite taking metformin 1000 mg twice daily and glyburide 10 mg daily for a few months. Today, MJ comes to pick up her refills and begins to discuss her diabetes control with you. She reports taking her medications daily and that gaining better control of her diabetes is a priority to her, but states, “I am not ready to start injecting myself and prefer to stick to pills.” Her provider would like to initiate a third agent.
What options are available to MJ?
Dr. Sobieraj is assistant professor of pharmacy practice and Dr. Coleman is associate professor of pharmacy practice and director of the pharmacoeconomics and outcomes studies group at the University of Connecticut School of Pharmacy.


Related Articles
Recent study results have indicated that female smokers may be at higher risk for developing menstrual pain.
The FDA has identified 11 cases of pulmonary hypertension in infants and newborns treated with diazoxide (Proglycem).
Sandoz has launched a generic version of the injectable anticoagulant, bivalirudin (Angiomax), following a completed supply and distribution deal with The Medicines Company.
The 2013 American College of Cardiology/American Heart Association guidelines for determining statin eligibility more accurately identify increased risk of cardiovascular events.
Latest Issues
$auto_registration$